Moderna, Inc. (NASDAQ:MRNA) President Sells $1,575,300.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction on Monday, April 15th. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the completion of the transaction, the president now owns 1,486,241 shares in the company, valued at $156,085,029.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Stephen Hoge also recently made the following trade(s):

• On Thursday, February 29th, Stephen Hoge sold 2,388 shares of Moderna stock. The shares were sold at an average price of $94.57, for a total value of $225,833.16.

Moderna Trading Down 0.6 %

Shares of Moderna stock opened at $101.41 on Friday. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $144.43. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The business has a 50 day moving average price of $100.63 and a 200 day moving average price of $93.64. The company has a market capitalization of $38.83 billion, a P/E ratio of -8.17 and a beta of 1.62.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. During the same quarter last year, the business posted $3.61 earnings per share. Moderna’s revenue was down 44.9% compared to the same quarter last year. Sell-side analysts anticipate that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Douglas Lane & Associates LLC boosted its position in Moderna by 36.4% during the third quarter. Douglas Lane & Associates LLC now owns 355,177 shares of the company’s stock worth $36,686,000 after acquiring an additional 94,810 shares during the last quarter. International Assets Investment Management LLC boosted its holdings in shares of Moderna by 6,528.9% during the fourth quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after purchasing an additional 381,808 shares during the last quarter. ARK Investment Management LLC grew its position in shares of Moderna by 81.7% in the third quarter. ARK Investment Management LLC now owns 259,838 shares of the company’s stock valued at $26,839,000 after purchasing an additional 116,840 shares during the period. Kentucky Retirement Systems Insurance Trust Fund acquired a new position in Moderna in the third quarter valued at $1,185,000. Finally, Invesco Ltd. lifted its position in Moderna by 19.8% during the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after buying an additional 517,683 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MRNA. HSBC restated a “reduce” rating and set a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. William Blair reissued a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Jefferies Financial Group restated a “buy” rating and set a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. Canaccord Genuity Group increased their price target on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a report on Friday, February 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $125.00 price objective on shares of Moderna in a report on Thursday, March 28th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Moderna has an average rating of “Hold” and an average price target of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.